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Copper ions are needed for several hallmarks of cancer. However,
the involved pathways, mechanisms, and copper-binding proteins
are mostly unknown. We recently found that cytoplasmic Antioxi-
dant 1 copper chaperone (Atox1), which is up-regulated in breast
cancer, is localized at the lamellipodia edges of aggressive breast
cancer cells. To reveal molecular insights into a putative role in cell
migration, we here investigated breast cancer cell (MDA-MB-231)
migration by video microscopy as a function of Atox1. Tracking of
hundreds of individual cells (per condition) over a 9-h time series
revealed that cell migration velocity and directionality are signifi-
cantly reduced upon Atox1 silencing in the cells. Because silencing
of the copper transporter ATP7A also reduced cell migration, these
proteins appear to be on the same pathway, suggesting that their
well-known copper transport activity is involved. In-cell proximity
ligation assays demonstrated that Atox1, ATP7A, and the proen-
zyme of lysyl oxidase (LOX; copper-loaded via ATP7A) are all in close
proximity and that LOX activity is reduced upon Atox1 silencing in
the cells. Since LOX is an established player in cancer cell migration,
our results imply that Atox1 mediates breast cancer cell migration
via coordinated copper transport in the ATP7A-LOX axis. Because
individual cell migration is an early step in breast cancer metastasis,
Atox1 levels in tumor cells may be a predictive measure of metasta-
sis potential and serve as a biomarker for copper depletion therapy.
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Many proteins coordinate copper (Cu) ions to facilitate bi-ological processes such as cellular respiration, protection
against oxidative stress, biosynthesis of chemical messengers,
modulation of connective tissue, and pigment construction (1–3).
The concentrations and locations of Cu in cells are regulated via
a set of so-called Cu transport proteins that handle Cu uptake
and export as well as selective delivery to Cu-dependent enzymes
(4–6). Soluble, cytoplasmic Antioxidant 1 copper chaperone (Atox1)
(7) collects Cu that has entered the cell and delivers the metal to
two multidomain P1B-type ATPases (adenosine triphosphatases)
in the trans-Golgi network called ATP7A and ATP7B. Several
Cu-dependent enzymes found in humans acquire Cu from ATP7A
(e.g., lysyl oxidase) and ATP7B (e.g., ceruloplasmin) before further
transport to specific locations for functioning (4–6). Whereas
Atox1 is expressed in all cells, ATP7A and ATP7B expression
depends on cell type: ATP7B is found mostly in hepatic cells;
ATP7A, in most other cells (http://www.proteinatlas.org/).
Because Cu is important as a cofactor in many biological pro-
cesses (8–10), it is no big surprise that Cu is required in several
distinguishing cancer phenomena (such as metastasis) and that
cancer patients’ serum and tumors have increased Cu levels (11).
Metastasis begins with migration of individual cancer cells that
detach from the primary tumor. Such cancer cells first invade local
tissue and then migrate through the tumor stroma and blood
vessels to eventually reach distant metastatic sites where they start
to grow (12). Local cell migration is accomplished by the creation
of actin-rich plasma membrane protrusions (e.g., lamellipodia) at
the leading edge of the cell. Cu can promote the capacity of cancer
cells to metastasize through activation of enzymes involved in cell
growth and metabolism, such as the Cu-dependent proteins lysyl
oxidase (LOX) (13, 14), SPARC (secreted protein acidic and rich
in cysteine or osteonectin) (15), MEK1 (mitogen-activated protein
kinase kinase 1) (16), and MEMO1 (mediator of cell motility 1)
(17). Whereas it is not known how SPARC, MEK1, and MEMO1
are loaded with Cu for LOX, a Cu-dependent amine oxidase, there
is information on both Cu loading and functions. ATP7A loads Cu
into the secretory compartment for eventual loading onto LOX
before secretion and proteolytic cleavage to a propeptide (LOXPP)
and mature LOX (18–20). The Cu-dependent activity of LOX in-
cludes cross-linking of collagen and elastin in the extracellular
matrix (ECM) (21). Cancer cells secrete LOX to create premeta-
static niches by stimulating collagen cross-linking and fibronectin
synthesis (14, 22) that in turn promote tumor cell migration and
adhesion (23–25). In addition to extracellular activities, LOX may
also regulate cancer cell migration via (less-known) intracellular
activities, such as modulation of actin polymerization (26, 27).
Cu transport proteins may play key roles in cancer through
loading of Cu-dependent enzymes with Cu (28, 29), but they may
also have additional functions related to cancer. For example,
Atox1 was shown to act as a Cu-dependent transcription factor that
promotes expression of cyclin D1 (30), a key protein involved in cell
proliferation (31), and it promotes inflammatory neovascularization
by acting as both a transcription factor and a cytoplasmic Cu
chaperone (32). In addition, Atox1 was described to be essential for
platelet-derived growth factor (PDGF-) –induced cell migration
(33) through a mechanism that involves translocation of ATP7A
and the small G protein known as Rac family small GTPase 1
(Rac1) to the leading edge of cells for lamellipodia formation (34).
To identify overexpressed Cu transport proteins in cancer, we
previously analyzed the RNA transcript level changes of the whole
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Cu proteome (i.e., for 54 identified Cu-binding proteins) in dif-
ferent cancer tissues using information from the Cancer Genome
Atlas (TCGA) database (35). Our analysis revealed that, with re-
spect to Atox1, it is up-regulated in breast, colorectal, uterus, and
liver tumors (35), and the breast cancer data were confirmed by us
in tissue microarray experiments. Next, using two breast cancer cell
lines, MDA-MB-231 (i.e., MDA-231) and MCF7, we found that
Atox1 accumulates at lamellipodia borders of the cells. Atox1 si-
lencing in MDA-231 cells resulted in apparent cell migration de-
fects as evidenced by reduced wound closure in a wound-healing
assay (36), although this assay not only probes cell migration but
also reflects cell proliferation and cell-cell interactions (37). To
specifically probe the role of Atox1 in the migration of individual
breast cancer cells, we here applied live-cell video microscopy in
combination with Atox1 silencing. Notably, this methodology al-
lows for quantitative measurements of individual cell migration
parameters; in addition, morphological changes in cells during
migration, as well as cell death and proliferation, can be identified.
The results we present demonstrate that Atox1 is needed for two-
dimensional (2D) MDA-231 single-cell migration with respect to
both velocity and directionality. Building on a recent report that
showed the ATP7A-LOX pathway to be required for breast cancer
metastasis (20), we used in-cell proximity ligation and LOX activity
assays to demonstrate that the same pathway, with Atox1 added as
an upstream partner, is responsible for single-cell migration in
MDA-231 breast cancer cells.
Results
Atox1 Silencing Reduces Single-Cell Migration Velocity and Directionality.
Boyden chamber migration assays demonstrated that knockdown of
Atox1 expression with silencing RNA (siRNA) reduces MDA-231
cell migration (SI Appendix, Fig. S1). This observation supports
our earlier finding of reduced wound healing for MDA-231 cells
upon Atox1 silencing (36). To study breast cancer cell migration
more quantitatively and at the single-cell level, we turned to 2D
video microscopy of low-density cell cultures followed by single-
cell tracking. In most experiments presented in this study, we
analyzed MDA-231 breast cancer cells with control (control
nontargeting siRNA) and silenced Atox1 expression levels in both
standard (0.26 μM Cu according to inductively coupled plasma
mass spectrometry [ICP-MS]) and 5 μM Cu-supplemented culture
medium (CM). Cell transfection with 28 nM Atox1-targeting
siRNA resulted in 50 and 60% reduced Atox1 expression levels at
30 and 48 h posttransfection, respectively (Fig. 1A). Thus, silenc-
ing reduced the Atox1 level but did not abolish all of the protein in
the cells. This was important as we did not want the cells to be
dramatically perturbed. Tracking analysis of hundreds of MDA-
231 cells per condition for the 9-h time series (Materials and
Methods; examples of tracking data are given in Movies S1–S4
with explanatory legends at the end of the SI Appendix) demon-
strated that cells with reduced Atox1 levels have less distributed
tracks (Fig. 1B). Specifically, the quantitative analysis showed that
the Atox1-silenced cells migrated with reduced velocity (me-
dian value of 0.41 versus 0.31 μm/min [standard CM] and 0.42
versus 0.30 μm/min [Cu-supplemented CM] for control versus
Atox1-silenced cells) and shorter Euclidean distance (median
value of 32.6 versus 15.7 μm [standard CM] and 32.6 versus 21.1 μm
[Cu-supplemented CM] for control versus Atox1-silenced cells) in
both CM conditions (Fig. 1C and SI Appendix, Fig. S2).
ICP-MS analysis of cell-associated Cu content showed that
control and Atox1-silenced cells had similar amounts of Cu. More-
over, the 5 μMCu treatment of the cells increased the cell-associated
Fig. 1. Silencing of Atox1 expression in MDA-231 breast cancer cells results in reduced cell migration velocity and Euclidean distance. Cell migration evaluation by
2D phase contrast video microscopy and single-cell tracking analysis (9-h video recorded between 30 and 48 h posttransfection, 1-min intervals) of MDA-231 cells
with control or reduced Atox1 expression levels in standard CM or 5 μMCu-supplemented CM (CM Cu). (A) Western blot analysis of Atox1 expression at 30 and 48 h
post transfection with control (siCtrl) or Atox1-targeting siRNA (siAtox1). Beta-actin expression was determined as loading control. Error bars indicate SD of the
mean (nExp = 3; statistics using Student’s t test). (B) Wind-rose plots show cell tracks (nExp = 3, nROI/Exp = 2, ntracked cells = 166, 170, 219, and 214 for siCtrl CM,
siCtrl CM + Cu, siAtox1 CM, and siAtox1 CM + Cu, respectively). (C) Box-whisker plots present migration velocity and Euclidean distance of the tracked cells (nExp =
3, nROI/Exp = 2; Mann–WhitneyU statistical test). The error bars indicate the minimum andmaximum values for the data sets (thus, the entire range of data is shown
in each case). *P < 0.05, **P < 0.01, ***P < 0.001.








Cu concentration four times in control cells and five times in
Atox1-silenced cells (SI Appendix, Table S1). We note that in all
presented experiments, regardless of Cu supplementation or not,
the cells had access to Cu and thus Atox1 could be Cu-loaded.
As a control for the tracking experiments, we counted the av-
erage number of cells per region of interest (ROI; 632.5 μm2). The
analysis revealed that the determined cell density, 84 cells (±9 SD)
per ROI, was comparable for control and Atox1-silenced cells in
both standard and Cu-supplemented CM (SI Appendix, Fig. S3).
This parameter is important to probe since variation in cell density
may influence the cell tracks.
ATP7A Silencing Reduces Single Breast Cancer Cell Migration Velocity
and Directionality. Since recent studies showed ATP7A to be
important for metastasis in a different breast cancer system (20)
and for stimulated migration of vascular smooth-muscle cells
(38), we decided to test if ATP7A is also involved here, with
Atox1, to promote MDA-231 breast cancer cell migration. To
test involvement of ATP7A, we assessed cell migration in control
versus ATP7A-silenced cells with the same methodology as for
Atox1. Cell transfections with 28 nM ATP7A siRNA resulted in
a 70 and 78% reduction in ATP7A expression at 30 and 48 h
posttransfection, respectively (Fig. 2A). Live-cell video micros-
copy followed by cell-tracking analysis demonstrated significantly
reduced migration velocity (median 0.44 versus 0.37 μm/min
[standard CM] and 0.38 versus 0.32 μm/min [Cu-supplemented
CM] for control versus ATP7A-silenced cells) and Euclidean
distance (median 45.17 versus 30.66 μm [standard CM] and 47.90
versus 32.39 μm [Cu-supplemented CM] for control versus
ATP7A-silenced cells) for cells with reduced ATP7A expression
levels in standard and Cu-supplemented CM (Fig. 2 B and C
and SI Appendix, Fig. S4). ATP7A silencing did not change cell-
associated Cu levels, as compared to control cells, in either
standard or Cu-supplemented CM as probed by ICP-MS (SI
Appendix, Table S1). In comparison to Atox1 silencing, the de-
crease in cell migration velocity upon ATP7A silencing was not
large. However, since the consequences on cell migration are
similar upon Atox1 silencing and ATP7A silencing, the two pro-
teins appear to be on the same pathway. As for the siAtox1 cell-
tracking experiments, we analyzed average cell number per ROI in
the ATP7A-related tracking experiments and found comparable
cell density: 90 cells (±8 SD) per ROI for control and ATP7A-
silenced cell conditions in both standard and Cu-supplemented
CM (SI Appendix, Fig. S5).
In control experiments, we assessed cell viability and pro-
liferation after treatment with siRNA and Cu. Cell viability was
not affected by any of the treatments (tested by erythrosine B
staining 24 h posttransfection). To evaluate cell proliferation, we
visually identified dividing cells in the time-lapse microscopy videos.
We observed no decrease in proliferation for Atox1-silenced cells
in standard CM, but in Cu-supplemented CM, Atox1-silenced cells
showed somewhat decreased proliferation compared to control
cells [similar to what was reported in HEK cells (39)]. Also, there
was a decrease in proliferation of ATP7A-silenced cells as com-
pared to control cells for both standard and Cu-supplemented CM
(SI Appendix, Fig. S6). Importantly, these variations in proliferation
for the different culture conditions did not affect our cell-tracking
results as only nonproliferative cells were tracked and analyzed.
Atox1, ATP7A, and LOX Are in Proximity with Interdependence in Breast
Cancer Cells. Because ATP7A-mediated activation of LOX was
found to be important for breast cancer metastasis in another
Fig. 2. Silencing of ATP7A expression results in reduced cell migration velocity and Euclidean distance. Cell migration evaluation by 2D phase contrast video
microscopy and single-cell tracking analysis (9-h video recorded between 30 and 48 h posttransfection, 10-min intervals) of MDA-231 cells with control or
reduced ATP7A expression levels in standard CM or 5 μM Cu-supplemented CM (CM + Cu). (A) Western blot analysis of Atox1 expression at 30 and 48 h
posttransfection with control siRNA (siCtrl) or ATP7A-targeting siRNA (siATP7A). Beta-actin expression was determined as loading control. Error bars indicate
SD of the mean (nExp = 2; statistics using Student’s t test). (B) Wind-rose plots with cell tracks for control (siCtrl) and ATP7A-silenced (siATP7A) cells in CM
and CM + Cu (nExp = 2, nROI/Exp = 2, ntracked cells = 134, 130, 132, and 106 for siCtrl CM, siCtrl CM + Cu, siATP7A CM, and siATP7A CM + Cu, respectively). (C) Box-
whisker plots presenting migration velocity and Euclidean distance of the tracked cells (nExp = 2, nROI/Exp = 2; Mann–Whitney U statistical test). The error bars
indicate the minimum and maximum values for the data sets. *P < 0.05, ***P < 0.001.
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model system (20), we decided to test if LOX is downstream of
Atox1-ATP7A in the pathway facilitating MDA-231 cell mi-
gration. Both ATP7A and LOX are overexpressed in MDA-231
cells (40). Here, we used an anti-LOXPP antibody that targets
the intracellular LOX proenzyme. First, we applied immuno-
fluorescent cell staining to locate Atox1, ATP7A, and LOXPP
in the MDA-231 breast cancer cells. As reported before for
Atox1 in these cells (36) and ATP7A in vascular smooth-muscle
cells (33), we found all three proteins to, in part, localize at the
lamellipodia borders (SI Appendix, Fig. S7). Then we tested
possible interactions between Atox1, ATP7A, and LOXPP using
in situ proximity ligation assays (PLAs) (41, 42). With this ap-
proach, protein-protein interactions could be probed with single-
molecule resolution. The concept builds on attaching specific
oligonucleotide probes to antibodies against two proteins of in-
terest; if the antibodies are in close proximity (<40 nm), the oli-
gonucleotides form circular DNA that can serve as a template for
localized rolling-circle amplification, which is then visualized in
situ as bright dots using fluorescence microscopy.
We first confirmed that we could detect the expected inter-
action of Atox1 and ATP7A in the MDA-231 cells using PLA (SI
Appendix, Fig. S8A) and performed several technical and bi-
ological negative controls (one primary antibody only and
Atox1-beta actin, respectively) (SI Appendix, Fig. S8B). Then we
probed the proximity of Atox1 and ATP7A individually, with the
LOX proenzyme (via LOXPP antibody) in the MDA-231 cells, in
both standard and Cu-supplemented CM. As expected, since
ATP7A delivers Cu to the LOX proenzyme, we detected ATP7A-
LOXPP proximity in the MDA-231 cells (Fig. 3A). Surprisingly, we
also detected Atox1-LOXPP proximity in the cells (Fig. 3B). This
implies that Cu delivery from Atox1 to ATP7A, and then from
ATP7A to the LOX proenzyme, is a synchronized chain of events.
To further test the relationship between the three proteins in
the MDA-231 cells, we evaluated Atox1-LOXPP and ATP7A-
LOXPP proximities as a function of ATP7A and Atox1 expres-
sion levels, respectively. Notably, we found the number of Atox1-
LOXPP interactions (fluorescent dots) per cell to decrease
significantly upon ATP7A silencing (by 48 and 47% in standard
and Cu-supplemented CM, respectively). This implies that the
presence of ATP7A is required for Atox1-LOXPP proximity.
Similarly, the number of ATP7A-LOXPP interactions (fluores-
cent dots) per cell decreased upon Atox1 silencing (by 25 and
44% in standard and Cu-supplemented CM, respectively).
Thus, the presence of Atox1 appears necessary for ATP7A-
LOXPP proximity (Fig. 3 A and B). We concluded that, in MDA-
231 breast cancer cells, the three proteins (Atox1, ATP7A, and
LOX) depend on each other for spatial proximity. As a control,
we analyzed total cellular levels of the three proteins after si-
lencing Atox1 and ATP7A. We found that neither Atox1 nor
ATP7A silencing changed the cellular levels of the other two
proteins (Fig. 3C). This supports that it is the spatial proximities
of Atox1 and LOX proenzyme proteins, or ATP7A and LOX
proenzyme proteins, that are disrupted upon ATP7A or Atox1
silencing, respectively.
To assess functional consequences of Atox1 silencing for LOX
activity, we probed LOX activity in the conditioned CM of the
cells using a LOX activity assay (fluorimetric) similar to what was
used by Petris et al. (20). We used ATP7A silencing as a positive
biological control, as Petris et al. showed that ATP7A knockout
reduced LOX activity in another metastatic breast cancer cell
model. In our experiments, silencing of ATP7A resulted in a
28% reduction in LOX activity and Atox1 silencing resulted in a
16% reduction in LOX activity (SI Appendix, Figs. S9 and S10 for
positive and negative technical controls). Notably, in these ex-




















Fig. 3. PLAs reveal proximity and interdependence between Atox1, ATP7A, and LOXPP. PLA data for Atox1-ATP7A, Atox1-LOXPP, and ATP7A-LOXPP in-
teractions in MDA-231 cells with control (siCtrl) or reduced expression levels of Atox1 (siAtox1) or ATP7A (siATP7A) in standard CM or 5 μM Cu-
supplemented CM (CM + Cu). (A) Maximum projection confocal micrographs (blue = DAPI, indicating the nucleus; green = PLA dots) merged with phase
contrast images. (Scale bars indicate 10 μm.) (B) Quantitative PLA results. Error bars indicate SD of the mean (nExp = 2 for Atox1-ATP7A, nExp = 3 for Atox1-
LOXPP and ATP7A/LOXPP, nROI/Exp = 5; statistics using Student’s t test). (C) Western blot, representative blots (Top), and quantitative results (Bottom). Error
bars indicate SD of the mean (nExp = 3). **P < 0.01, ***P < 0.001.








54 and 80%, respectively (SI Appendix, Fig. S11). These findings
demonstrate that Atox1 levels in the cells have direct effects on
LOX activity.
Discussion
Atox1 is up-regulated in tissue from several types of cancers (35).
In fact, if one analyzes patient data (e.g., https:/www.proteinatlas.org,
but there are several data bases), it becomes evident that breast
cancer patients with high Atox1 mRNA levels have poorer survival
than those with low Atox1 levels (SI Appendix, Fig. S12). Thus, the
level of Atox1 in cancer cells appears to be of direct clinical rel-
evance. Here we used live-cell video microscopy for single-cell
tracking, in combination with selective gene silencing, to demon-
strate that Atox1 is needed for fast and directional breast cancer
cell migration. This is an important result, as cell migration is
directly related to metastasis potential and thus patient survival.
We further showed that this effect appears mediated via the
ATP7A-LOX axis. ATP7A silencing results in decreases in cell
migration similar to those detected for Atox1 silencing, and the
three proteins (Atox1, ATP7A, and LOX) are found in close
proximity in breast cancer cells. Furthermore, we showed that si-
lencing of Atox1 reduces LOX activity and, since LOX is a known
mediator of cancer cell migration and metastasis (23–25) and
LOX activity was found to be essential for migration of single
MDA-231 cells (23), this provides a mechanistic explanation for
the Atox1 effects. In other words, the promoting role of Atox1 for
MDA-231 cell migration appears facilitated via coordinated
Atox1-mediated Cu delivery to ATP7A and further to LOX, with
Cu-loaded, activated LOX in turn promoting processes that
stimulate cell migration.
Earlier work showed Atox1 to be important for PDGF-stimulated
smooth-muscle cell migration, and it was suggested that in these
cells Atox1 mediates migration via interactions with ATP7A and
Rac1 (34). This work was followed by another study, using the
same smooth-muscle cells, where it was shown that cell migration
is promoted by ATP7A interactions with IQGAP1 (IQ motif
containing GTPase activating protein 1) and Rac1, whereby all
proteins translocate to the leading edge of the cells (38). IQGAP1
is a Rac1-binding scaffolding protein that plays a central role in the
assembly of signaling complexes that regulate cellular motility,
morphogenesis, and cell adhesion (43). Since we found ATP7A to
be important for migration of MDA-231 breast cancer cells, we
also tested if IQGAP1 plays a role. However, a pathway involving
IQGAP1 appears not to dominate migration of MDA-231 breast
cancer cells, as IQGAP1 silencing did not affect cell migration in
live-cell–tracking experiments (SI Appendix, Fig. S13). Our pre-
sented results are instead similar to the findings described by Petris
et al. (20). In this work, ATP7A-mediated activation of LOX was
required for LOX-related mechanisms of metastasis of 4T1
mammary and Lewis lung carcinoma cells. In similarity to the
Atox1 data in SI Appendix, Fig. S12, Petris et al. showed that breast
cancer patients with high ATP7A expression levels in the primary
tumor have reduced survival chances (20). Based on our current
findings on Atox1 in MDA-231 cells, we predict that Atox1 is also
a key upstream partner of ATP7A-LOX in 4T1 mammary and
Lewis lung carcinoma cells that aids in promotion of metastasis.
Taken together, our results demonstrate a key role for Atox1
in individual cell migration of aggressive breast cancer cells.
Individual cancer cell migration relates closely to what happens
when a tumor begins to metastasize (44). With our methodology
(i.e., live-cell time-lapse video microscopy followed by cell tracking),
we specifically probed migration kinetics of individual cells and
at the same time kept track of other cellular processes such as
death and proliferation. In contrast, more common and easier
cell migration assays (such as wound healing) often only report
on endpoint outcomes and the results are affected by cell pro-
liferation and cell-cell contacts. We further connected the Atox1
effect on cell migration to cellular activities of partner proteins
ATP7A and LOX. Our work thus extends and links (in breast
cancer) earlier work showing Atox1 being important for vascular
smooth-muscle cell migration (33), and ATP7A and LOX being
important for breast cancer metastasis (20). Although we did not
prove a Cu dependence (in all experiments, cells had access to
Cu; a four- to sixfold change in cell-associated Cu amount did
not change the observed cell migration trends), Atox1 likely
mediates breast cancer cell migration via Cu delivery to ATP7A,
which delivers the metal to the LOX proenzyme. This in turn
results in secreted, activated LOX. With all three proteins near
each other in the cell and, in part, at the leading edge, the re-
sponse to external cues may be at its most efficient, which is
important when there is a high demand of Cu (such as in cancer).
Due to this activity, Atox1 may act as a biomarker for breast
cancer metastasis, such that patients with high Atox1 levels in
primary tumor cells are at higher risk of metastasis than those
with low Atox1 levels. Patients with high Atox1 would benefit the
most from copper chelation therapy, which is an approach cur-
rently under investigation in clinical trials (45). In connection
with clinical studies, quantification of migration properties of
cancer cells using time-lapse microscopy may be a useful tool in
the study of potential therapeutic anticancer drugs as well as in
the discovery of molecular pathways of metastasis.
Materials and Methods
Video Microscopy and Cell Tracking. Cells were seeded in plates with poly-L-
lysine–coated glass bottoms. Upon cell adhesion, each plate was positioned
into a stage top incubator on an Eclipse Ti 2 inverted microscope (Nikon).
Cells were automatically imaged over time using phase contrast microscopy
at multiple positions per well using a 10× air objective (Nikon). Cell tracking
was performed manually for all selected cells. Further details are given in SI
Appendix, Extended Materials and Methods.
In Situ Proximity Ligation Assay. PLA was performed on fixed MDA-231 cells
using the Duolink Detection Reagents Green Kit (Sigma-Aldrich) according to
the manufacturer’s instructions. Full details are given in the SI Appendix,
Extended Materials and Methods.
LOX Activity. LOX activity was measured in the conditioned CM of control
Atox1- and ATP7A-silenced cells using a fluorescence-based LOX activity kit
(Abcam) according to the manufacturer’s instructions. Full details are given
in the SI Appendix, Extended Materials and Methods.
Other Methods. Cell lines, siRNAs, and reagents used are described in the SI
Appendix, Extended Materials and Methods. Details on the Boyden chamber
assay, Western blotting, immunofluorescence microscopy, Cu treatment,
cell-associated Cu analysis by ICP-MS, and clinical association analysis are
given in the SI Appendix, Extended Materials and Methods.
Data Availability. All data and procedures are provided here and in the
SI Appendix.
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